DuPont purchases enzyme assets from Dyadic

On December 31, 2015 Dyadic announced the closing of the sale of substantially all of the assets of its Industrial Technology business to DuPont’s Industrial Biosciences business, including Dyadic’s C1 platform.

Learn More

BiofuelsBiochemicalsBiopharmaceuticalsAnimal FeedPulp and PaperTextilesFood and BeverageNutraceuticals

Welcome to Dyadic. We are a global biotechnology company with patented and proprietary technologies that are used to discover, develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic’s C1 platform technology enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. Dyadic leverages the value of its technologies through licensing arrangements and other collaborations with third parties who receive the benefits of producing and using the proteins these technologies help produce. LEARN MORE

Recent News

January 19, 2016
Dyadic Announces Robert Burke Resignation
Click Here

January 12, 2016
Dyadic Announces Purchase of Abengoa Stock
Click Here

December 31, 2015
Dyadic Announces Closing of Sale of Industrial Technology Business
Click Here

December 31, 2015
The C1 Expression System - Redefining Biosimilar Production
Click Here

Upcoming Events

CEO Mark A. Emalfarb attends JP Morgan 34th Annual Healthcare Conference, January 11 - 14, 2016 in San Francisco, CA


SNNLive Interview with Mark Emalfarb, CEO and Founder, Dyadic International, Inc
October 2015

Mark Emalfarb Presentation at 2015 BIO World Congress in Montreal
July 19-22, 2015

Mark Emalfarb Interview at LD Micro VI
Los Angeles, December 3-5, 2013